TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

TD Cowen analyst Dan Brennan has maintained a Buy rating on Adaptive Biotechnologies (NASDAQ: ADPT) and raised the price target from $28 to $32.